Corticotropin Releasing Factor Receptor Function in CNS

Information

  • Research Project
  • 6484499
  • ApplicationId
    6484499
  • Core Project Number
    R43MH065720
  • Full Project Number
    1R43MH065720-01
  • Serial Number
    65720
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/4/2002 - 23 years ago
  • Project End Date
    3/31/2005 - 20 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    4/4/2002 - 23 years ago
  • Budget End Date
    3/31/2005 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/4/2002 - 23 years ago

Corticotropin Releasing Factor Receptor Function in CNS

DESCRIPTION (provided by applicant): Corticotropin releasing factor (CRF) receptors are involved in the stress response; CRF produces generalized arousal and anxiety-like behaviors in rodents. Two related genes encode the CRF1 and CRF2 receptor subtypes, which exhibit distinct expression patterns in the brain. Paradoxically, the brain areas involved in stress-related autonomic responses express low or undetectable levels of CRF receptors. In addition, the role of CRF in brain regions that express the highest levels of CRF receptors (e.g. cortex and cerebellum) remains unexplored. CRF1 and CRF2 are G-protein coupled receptors but the functional consequences of receptor activation are poorly understood. Electrophysiological experiments are needed to elucidate how CRF affects neuronal function. A major obstacle to conducting these experiments is identifying the neurons that express CRF receptors in brain slices. We propose to non-destructively label neurons that express CRF receptors by the targeted expression of fluorescent proteins in transgenic mice. We will generate two transgenic mouse lines labeling neurons that express CRF1 and CRF2, respectively in order to unequivocally identify them for electrophysiological recording. These animals will be used to expand our understanding of CRF receptor function as well as to develop secondary assays for the development CRF receptor subtype selective antagonists as therapeutic agents. PROPOSED COMMERCIAL APPLICATION: Small molecule antagonists to CRF receptors are proposed to be therapeutic for treating anxiety and depression. Yet the mechanism by which the CRF system affects brain function is unknown. This research will produce and important tool for studying the function of CRF receptors in situ. It will enable development of functional (electrophysiological) assay(s) for CRF receptors in a native system and lead to the development of optimal small molecule drugs that target the CRF system.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R43
  • Administering IC
    MH
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    170479
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    242
  • Ed Inst. Type
  • Funding ICs
    NIMH:170479\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NEUROCRINE BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    800981276
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921302007
  • Organization District
    UNITED STATES